Cardax Inc · OTC:CDXI
Cardax — Investor Presentation (November 2020)
19 slides from Cardax's investor presentation, Nov 18, 2020
Slide 1: Corporate Presentation November 2020
“° cardax CORPORATE PRESENTATION November 2020
Slide 2: Major Unmet Medical Need
MAJOR UNMET MEDICAL NEED Everyday, anti-inflammatory for cardiovascular disease with excellent safety profile CARDAX, INC. Biopharmaceutical company founded in 2006 (OTCQB:CDxXI) HUMAN PROOF OF CONCEPT Reduction of inflammation, lipids, and blood pressure, with no side effects, in cardiovascular pop
Slide 3: Management Team
MANAGEMENT TEAM David G Watumull - Chief Executive Officer Co-founder of Cardax and co-inventor of technology. Experienced biotech executive, former biotech analyst and investment banker. David M Watumull - Chief Operating Officer ‘Two decades of experience in astaxanthin product development, commer
Slide 4: Board of Directors and Scientific Advisory Board
BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD George W Bickerstaff - Chairman Former Chief Financial Officer of Novartis Pharma. David G Watumull - Director Chief Executive Officer of Cardax. Terence A Kelly, PhD — Director Former research executive with Boehringer Ingelheim. Michele Galen — Director
Slide 5: Cardax Product Platform
CARDAX PRODUCT PLATFORM PHARMACEUTICAL CANDIDATES CDX-101 (ASTAXANTHIN RX CANDIDATE) for SEVERE HYPERTRIGLYCERIDEMIA, CDX-301 (ZEAXANTHIN RX CANDIDATE) for MACULAR DEGENERATION DIETARY SUPPLEMENTS ZANTHOSYN® (ASTAXANTHIN SUPPLEMENT) for INFLAMMATORY HEALTH DISCOVERY | PRECLINICAL | CLINICAL | ee DEV
Slide 6: What Is Astaxanthin?
WHAT IS ASTAXANTHIN? Astaxanthin is a naturally occurring marine carotenoid found in salmon, microalgae, krill, lobster, and crab. Carotenoids are natural pigments that impart coloration and support animal health and vitality. Astaxanthin is responsible for turning salmon and shellfish pink.
Slide 7: Without Astaxanthin, Salmon Are:
WITHOUT ASTAXANTHIN, SALMON ARE: Grey Small Have reproductive problems Prone to infections Too weak to swim upstream
Slide 8: Astaxanthin Research
ASTAXANTHIN RESEARCH 2,000+ peer reviewed papers More than 50 peer reviewed papers published by Cardax team members 50+ pilot human clinical trials 20+ randomized, double-blind, placebo-controlled human proof-of-concept studies Astaxanthin: A Novel Potential Treatment for Oxidative Stress ‘und Infla
Slide 9: Astaxanthin Safety
ASTAXANTHIN SAFETY No significant side effects reported in published human studies (over 1,800 subjects) e Long history of use in humans and animals e Extensive safety testing
Slide 10: Animal Proof of Concept
ANIMAL PROOF OF CONCEPT Triglycerides [§ 72% in ApoE(-/-) mice Re-thrombosis [Jj 84% in dogs Atherosclerosis 31% in LDLR(-/-) mice (aortic arch pictured below) LOW DOSE HIGH DOSE
Slide 11: Human Proof of Concept
HUMAN PROOF OF CONCEPT CARDAX ASTAXANTHIN Cardax CHASE clinical trial interim results displayed as median percentage changes from baseline to week 12. *p<0.05 “p<001 CHASE Clinical Trial (cardax Cardiovascular Health Astaxanthin Supplement Evaluation © Randomized, double-blind, placebo-controlled, I
Slide 12: CDX-101 Proprietary Astaxanthin Prodrug
PROPRIETARY ASTAXANTHIN PRODRUG Anti-inflammatory activity, pleiotropic effects, excellent safety profile CDX-101 Cardax Astaxanthin Rx Candidate PROOF OF CONCEPT Human & animal studies with astaxanthin support safety and efficacy, de-risk development (current stage: pre-clinical; ~12-18 months to I
Slide 13: CDX-101 Next Steps
CDX-101 NEXT STEPS e Pre-IND Meeting: Q1-Q2 2021 e CMC o Development: Q1-Q3 2021 o Tox Batch: Q3 2021 o Clinical Batch: Q4 2021 - Q] 2022 e Non-Clinical Studies o ~©PK: Q3. 2021 °o Tox: Q4 2021 e IND: Q1 2022 (+/-3 months) ct to adjustment. Assumes adequate financing, 13
Slide 14: ZanthoSyn Overview
ZANTHOSYN® OVERVIEW ZanthoSyn’® is a p d astaxanthin dietary supplement for inflammatory health Superior Absorption 285x better absorption vs. ordinary astaxanthin Superior Purity Precision & purity (cGMP) e Noaftertaste or smell . [Sa Superior Safety ZanthoSyn ZanthoSyn © Generally Recognized as Sa
Slide 15: CDX-101 vs. ZanthoSyn
CDX-101 vs. ZANTHOSYN® While both deliver astaxanthin to the bloodstream, we believe the unique molecular structure of CDX-101 and its pharmaceutical pathway will provide substantial differentiation. COMPOSITION INTELLECTUAL PROPERTY PRODUCT TYPE (CHANNEL ECONOMICS DOSAGE CDX-101 synthetic Astaxanth
Slide 16: Major Unmet Medical Need
MAJOR UNMET MEDICAL NEED CARDAX, INC. Biopharmaceutical company HUMAN AMARIN / STRONG PROOF OF MATINAS INTELLECTUAL CONCEPT ANALOGUE PROPERTY 16
Slide 17: Thank You
THANK YOU
Slide 18: Certain Disclaimers
CERTAIN DISCLAIMERS ‘There are statements in this presentation that are not historical facts. These “forward-looking statenents” can be identified by use of terminology such as “anticipate” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “propose,” “should,
Slide 19: Certain Disclaimers (Continued)
CERTAIN DISCLAIMERS (CONTINUED) Securities are offered by US Capital Global Securities, LLC ("USCGS"), a SEC registered broker-dealer and member of FINRA/SIPC. US Capital Global Investment Management, LLC ("USCGIM"), the investment manager of the offering, USCGS, the placement agent for this offerin